Fig. 3
STOML2 promotes CRC growth and progression in vivo. a-e Subcutaneous implantation of STOML2-overexpressed MC38 cells (MC38-STOML2) and control group (MC38-mock) in C57BL/6 mice. (a) Tumor growth curves measured at indicated time points between MC38-STOML2 and -mock. *P < 0.05, two-way ANOVA. (b) 2 × 106 cells were injected into hind limbs of each group; tumors were retrieved at 21st day after injection. (c) Tumor weight (g) measured at retrieval. *P < 0.05, t test. (d) Representative image of HE staining of subcutaneous implant in each group. Scale bar, 40 μm.. (e) Representative images of IHC staining show positive correlation between Ki-67 and STOML2 overexpression in subcutaneous implant in each group. Scale bar, 40 μm. (f) Relative intensity of Ki-67 staining, **P < 0.01, t test. g-l Subcutaneous implantation of STOML2-knockdown MC38 cells (MC38-shSTOML2) and control group (MC38-scr) in C57BL/6 mice. (g) Tumor volume (cm3) measured at indicated time point. **P < 0.01, two-way ANOVA. (h) 2 × 106 cells were injected into hind limbs of each group; tumors were retrieved at 27th day after injection. (i) Tumor weight (g) measured at retrieval. **P < 0.01, t test. (j) Representative image of HE staining of subcutaneous implant in each group. Scale bar, 40 μm. (k) Representative images of IHC staining show negative correlation between Ki-67 and STOML2 knockdown in subcutaneous implant in each group. Scale bar, 40 μm. (l) Relative intensity of Ki-67 staining, **P < 0.01, t test. m-o CRC orthotopic injection of MC38-Scr and –shSTOML2 cells, murine endoscopy monitoring and survival curve. (m) 1 × 106 cells of each group were injected into each C57BL/6 colon sub-mucosa under endoscopy. White arrow indicates needle. (n) Endoscopy monitoring of orthotopic tumor growth in each group. (o) Kaplan-Meier survival curve of mice in each group. P value was determined using log-rank test